Abstract | BACKGROUND: AIM: To define an adequate cut-off for the PCI and to appraise whether SB involvement exerts an impact on this cut-off. PATIENTS AND METHODS: Patients (n = 139) treated with CCRS plus HIPEC were prospectively verified and retrospectively analyzed. One hundred presented with SB involvement of different extents and at different locations. RESULTS: All the patients with a PCI ≥ 15 exhibited SB involvement. Five-year overall survival was 48% when the PCI was <15 vs 12% when it was ≥ 15 (p < 0.0001. The multivariate analysis retained two prognostic factors: PCI ≥ 15 (p = 0.02, HR = 1.8), and the involvement of area 12 (lower ileum) (p = 0.001, HR = 3.1). When area 12 was invaded, it significantly worsened the prognosis: 5-year overall survival of patients with a PCI <15 and area 12 involved was 15%, close to that of patients with a PCI ≥ 15 (12%) and far lower than that of patients with a PCI <15 and no area 12 involvement (70%). CONCLUSION: A PCI greater than 15 appears to be a relative contraindication for treatment of colorectal PM with CCRS + HIPEC. Involvement of the lower ileum is also a negative prognostic factor to be taken into consideration.
|
Authors | D Elias, A Mariani, A-S Cloutier, F Blot, D Goéré, F Dumont, C Honoré, V Billard, P Dartigues, M Ducreux |
Journal | European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
(Eur J Surg Oncol)
Vol. 40
Issue 11
Pg. 1467-73
(Nov 2014)
ISSN: 1532-2157 [Electronic] England |
PMID | 25086990
(Publication Type: Journal Article)
|
Copyright | Copyright © 2014. Published by Elsevier Ltd. |
Chemical References |
- Organoplatinum Compounds
- Oxaliplatin
- Irinotecan
- Camptothecin
|
Topics |
- Adult
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Camptothecin
(administration & dosage, analogs & derivatives)
- Carcinoma
(pathology, secondary, therapy)
- Cohort Studies
- Colorectal Neoplasms
(pathology, therapy)
- Disease-Free Survival
- Duodenal Neoplasms
(pathology, secondary, therapy)
- Female
- Humans
- Hyperthermia, Induced
- Ileal Neoplasms
(pathology, secondary, therapy)
- Infusions, Parenteral
- Intestine, Small
(pathology, surgery)
- Irinotecan
- Jejunal Neoplasms
(pathology, secondary, therapy)
- Male
- Metastasectomy
- Middle Aged
- Organoplatinum Compounds
(administration & dosage)
- Oxaliplatin
- Patient Selection
- Peritoneal Lavage
- Peritoneal Neoplasms
(pathology, secondary, therapy)
- Peritoneum
(pathology, surgery)
- Retrospective Studies
- Treatment Outcome
|